Evidence based screening for Down's syndrome. We should be prepared to re-examine entrenched practices.
作者信息
Raeburn S
出版信息
BMJ. 2000 Mar 4;320(7235):592-3. doi: 10.1136/bmj.320.7235.592.
Abstract
摘要
相似文献
1
Evidence based screening for Down's syndrome. We should be prepared to re-examine entrenched practices.
BMJ. 2000 Mar 4;320(7235):592-3. doi: 10.1136/bmj.320.7235.592.
2
Down's syndrome screening: where to now?
BJOG. 2001 Jun;108(6):559-61. doi: 10.1111/j.1471-0528.2001.00129.x.
3
Serum screening for Down's syndrome. Private screening is problematic.
BMJ. 1993 Aug 21;307(6902):501. doi: 10.1136/bmj.307.6902.501-a.
4
Presentation of screen negative results on serum screening for Down's syndrome: variations across Britain.
J Med Screen. 1997;4(1):21-2. doi: 10.1177/096914139700400108.
5
Second trimester screening for Down's syndrome: 7 years experience.
J Med Screen. 2001;8(3):128-31. doi: 10.1136/jms.8.3.128.
6
Screening for Down's syndrome.
BMJ. 1994 Sep 24;309(6957):753-4. doi: 10.1136/bmj.309.6957.753.
7
Serum screening for Down's syndrome. Informed consent is vital..
BMJ. 1993 Aug 21;307(6902):500-1. doi: 10.1136/bmj.307.6902.500-c.
8
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):769-70; author reply 771. doi: 10.1136/bmj.305.6856.769-c.
9
Serum screening for Down's syndrome. Existing tests not good enough.
BMJ. 1993 Aug 21;307(6902):501-2. doi: 10.1136/bmj.307.6902.501-c.
10
Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution.
Br Med J (Clin Res Ed). 1985 Jun 29;290(6486):1940-3. doi: 10.1136/bmj.290.6486.1940.
引用本文的文献
1
Association of Down's syndrome and water fluoride level: a systematic review of the evidence.
BMC Public Health. 2001;1:6. doi: 10.1186/1471-2458-1-6. Epub 2001 Jul 24.
本文引用的文献
1
Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans.
BMJ. 2000 Mar 4;320(7235):606-10. doi: 10.1136/bmj.320.7235.606.
2
Down's syndrome screening in the UK in 1998.
Lancet. 1999 Oct 9;354(9186):1264. doi: 10.1016/s0140-6736(99)03819-2.
3
Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency.
Prenat Diagn. 1999 May;19(5):458-62. doi: 10.1002/(sici)1097-0223(199905)19:5<458::aid-pd569>3.0.co;2-a.
4
Ultrasound imaging of fetal neck anomalies: implications for the risk of aneuploidy and structural anomalies.
Prenat Diagn. 1997 Nov;17(11):1055-8. doi: 10.1002/(sici)1097-0223(199711)17:11<1055::aid-pd194>3.0.co;2-j.
5
Criteria for fetal nuchal thickness cut-off: a re-evaluation.
Prenat Diagn. 1997 Jan;17(1):23-9.
6
Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation.
Br J Obstet Gynaecol. 1995 Dec;102(12):957-62. doi: 10.1111/j.1471-0528.1995.tb10902.x.
7
Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group.
Br J Obstet Gynaecol. 1996 May;103(5):407-12. doi: 10.1111/j.1471-0528.1996.tb09765.x.
8
Prenatal diagnosis and genetic screening. Community and service implications. Summary and recommendations of a report of the Royal College of Physicians.
J R Coll Physicians Lond. 1989 Oct;23(4):215-20.
9
Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
BMJ. 1992 Aug 15;305(6850):391-4. doi: 10.1136/bmj.305.6850.391.
Zotero 插件